Sarzi-Puttini, P. and Atzeni, F. and Schölmerich, J. and Cutolo, M. and Straub, R. H. (2006) Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Annals of the rheumatic diseases 65 (3), pp. 301-5.
Download (437kB) - Repository staff only
Other URL: http://dx.doi.org/10.1136/ard.2005.040816
BACKGROUND: Insulin-like growth factor 1 (IGF1) is an important determinant of muscle mass because it promotes growth and suppresses protein degradation. IGF1 is decreased in rheumatoid arthritis and juvenile idiopathic arthritis because its synthesis is inhibited by inflammation. In parallel, glucocorticoids induce IGF1 resistance and add to muscle degradation. OBJECTIVE: To investigate the ...
Export bibliographical data
|Institutions:||Medicine > Lehrstuhl für Innere Medizin I|
|Keywords:||rheumatoid arthritis; adalimumab; insulin-like growth factor 1; IGF1 binding protein-1; IGF1 binding protein-3|
|Dewey Decimal Classification:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||06 Dec 2006|
|Last Modified:||13 Mar 2014 09:42|